Organon & Co OGN.N, OGN is expected to show a fall in quarterly revenue when it reports results on November 10 for the period ending September 30 2025
The Jersey City New Jersey-based company is expected to report a 0.4% decrease in revenue to $1.575 billion from $1.58 billion a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Organon & Co is for earnings of 94 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and 4 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Organon & Co is $10.50, about 36.1% above its last closing price of $6.71
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | 0.95 | 0.95 | 1.00 | Beat | 5.5 |
Mar. 31 2025 | 0.90 | 0.90 | 1.02 | Beat | 13.6 |
Dec. 31 2024 | 0.86 | 0.87 | 0.90 | Beat | 3.9 |
Sep. 30 2024 | 0.90 | 0.90 | 0.87 | Missed | -3.7 |
Jun. 30 2024 | 1.08 | 1.08 | 1.12 | Beat | 4.1 |
Mar. 31 2024 | 1.22 | 0.97 | 1.22 | Beat | 25.7 |
Dec. 31 2023 | 0.81 | 0.83 | 0.88 | Beat | 6 |
Sep. 30 2023 | 1.05 | 1.06 | 0.87 | Missed | -17.7 |
This summary was machine generated November 7 at 15:24 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)